Overview

* Globus Medical ( GMED ) Q3 sales rose 22.9% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, growing 42.6% yr/yr

* Company executed $40 mln in share repurchases, totaling $255.5 mln in 2025

Outlook

* Company raises 2025 revenue guidance to $2.86-$2.90 bln from $2.80-$2.90 bln

* Globus Medical ( GMED ) expects 2025 non-GAAP EPS of $3.75-$3.85, up from $3.00-$3.30

* Company anticipates Nevro acquisition to be accretive to 2025 earnings

Result Drivers

* US SPINE GROWTH - 10% growth in US Spine business contributed to overall revenue increase, per CEO Keith Pfeil

* NEVRO ACQUISITION - Nevro business exceeded expectations, supporting integration strategy and future growth

* SYNERGY CAPTURE - Improved gross margins and operating expenses due to synergy capture from mergers and acquisitions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $769 mln $734.35

mln (12

Analysts

)

Q3 Beat $1.18 $0.78

Adjusted (12

EPS Analysts

)

Q3 EPS $0.88

Q3 Net $119 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Globus Medical Inc ( GMED ) is $78.00, about 21.1% above its November 5 closing price of $61.51

* The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)